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Background: The human amylase gene (AMY1) has broad copy number (CN) 2 
variation that may associate with BMI.  3 
Methods: DNA was extracted from urine (n=74) and serum (n=6) samples 4 
(‘ProFiMet’ cohort), and buccal (n=17) samples (Oral Starch Challenge [OSC] 5 
cohort), and assessed for AMY1 CN by droplet digital PCR. Association of AMY1 CN 6 
with comprehensive markers of metabolic status (ProFiMet cohort) were analysed 7 
with Pearson Correlation Coefficients (CC). For the healthy, euglycemic OSC cohort, 8 
glycemic response to OSC was analysed with independent-sample t-tests 9 
(subgroups: high AMY1 CN 9-12, n=10; low AMY1 CN 4-6, n=7). 10 
Results: There were significant inverse correlations of AMY1 CN with total visceral 11 
fat volume (CC -0.33; P=0.004), and positive correlations of AMY1 CN with oral 12 
glucose insulin sensitivity score (OGIS [derived from OGTT], CC 0.26; P=0.02), 13 
serum HDL-cholesterol (CC 0.325; P=0.003), and serum adiponectin (CC 0.249; 14 
P=0.026). Linear regression multivariate analysis (adiponectin as dependent 15 
variable), showed independent association of adiponectin with AMY1 CN 16 
(Beta=0.29; P=0.03). There were no significant associations between AMY1 CN and 17 
clamp-derived M-value, homeostasis model assessment of insulin resistance (IR), 18 
hepatic endogenous glucose production, fecal floral signature or macronutrient 19 
dietary preference. Delta (mean) change in blood glucose concentration (fasting to 20 
30-min post-OSC), was significantly greater in the high vs low AMY1 CN subgroups 21 
(mean 1.7mmol/l [SEM 0.6] vs 0.9mmol/l [SEM 0.9] respectively; p=0.016).  22 
Conclusions: High AMY1 CN associates with favourable metabolic profile (lower 23 
visceral fat volume; higher serum adiponectin; enhanced glucose absorption 24 
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The World Health Organization (WHO) estimated global prevalence of adult obesity 68 
at 13%, and childhood overweight and obesity at 18% in 2016 (1). As a global threat 69 
to human health and longevity, obesity underlies >50 weight-related conditions 70 
(including type 2 diabetes mellitus [T2D]), and contributes towards a substantive 71 
health-economic burden (1). Lifestyle choices (including diet and activity) influence 72 
body weight. However, body mass index (BMI) also has a heritability of 70% (2, 3), a 73 
small proportion of which (2.7%) associates with >90 genetic loci (2). Non-mutational 74 
genetic differences between individuals, including copy number variation (CNV) of 75 
some genes such as those encoding amylase (AMY), may underlie some of the 76 
‘missing’ heritability for BMI, identified from genome-wide association studies (3).  77 
 78 
The human salivary amylase (AMY1) and pancreatic amylase (AMY2) genes are 79 
located in a cluster on chromosome 1p21.1 (1, 4). The human genome reference 80 
assembly (hg19) shows a structure that includes three copies of the AMY1 gene 81 
repeat (designated AMY1A, AMY1B and AMY1C to define their chromosomal 82 
location), and two pancreatic amylase genes (designated AMY2A and AMY2B). The 83 
AMY1 coding region, and approximately 26.5kb of flanking sequence constitutes the 84 
AMY1 ‘copy-variable repeat unit’. Replicates of this repeat unit are 99.9% identical.  85 
Although the reference human genome shows only three replicates, in the general 86 
human population the AMY1 region displays remarkable CNV between individuals 87 
(5). The CNV of AMY1 is thought to originate from unequal crossing-over events 88 
between the highly homologous components of the gene cluster (6). This CNV 89 
appears to post-date the split of modern Humans and Neanderthals (7). Using 90 





and AMY1 was shown to be the most common rearrangement event, resulting in 92 
AMY1 CN ranging from 2 to 18 per diploid genome (8).  93 
 94 
Salivary amylase plays a key role in starch digestion during mastication of food (9), 95 
through facilitating hydrolysis of 1,4-glycosidic bonds within starch, forming maltose, 96 
isomaltose, oligosaccharides and glucose (10, 11). Combined with the actions of 97 
pancreatic amylase within the ileum (encoded by the separate AMY2 amylase gene), 98 
ongoing hydrolysis of starch and its intermediate breakdown products, eventually 99 
results in the formation of absorbable free glucose (10). Human AMY1 copy number 100 
(CN) associates directly with concentration and activity of salivary amylase (10, 12-101 
15). 102 
 103 
In addition to its role in the production of salivary amylase for breakdown of starch 104 
during mastication, there is also evidence for association between AMY1 CN and 105 
BMI. Falchi and colleagues published the first report of an inverse association 106 
between human AMY1 CN and BMI using a quantitative Polymerase Chain Reaction 107 
(qPCR) approach (16). Replication in >6,000 participants from cohorts that included 108 
those of European and Singaporean Chinese ethnicities, demonstrated that each 109 
additional copy of AMY1 reduced obesity risk by 1.2-fold, and there was an 8-fold 110 
greater risk of obesity in individuals with an AMY1 CN<4, compared to those with an 111 
AMY1 CN>9 (16). Subsequent reported studies on AMY1 CNV and BMI have shown 112 
mixed results. Using a qPCR technique on a population from South Korea, Choi and 113 
colleagues showed an association between AMY1 CN and insulin sensitivity, but not 114 
with BMI (17). Using a different approach (digital PCR [dPCR]), Mejia-Benitez and 115 





appeared to be protective against obesity (18). In a different study reported by 117 
Viljakainen and colleagues, that utilized a superior ‘droplet digital’ PCR (ddPCR) 118 
technique (19) in a cohort of Finnish subjects with a history of severe childhood 119 
obesity, inverse association between AMY1 CN and both BMI and percentage body 120 
fat in the obese female subjects was shown (20). A further study by Bonnefond and 121 
colleagues on a French population of adults and children using ddPCR, also showed 122 
an association of higher AMY1 CN with reduced risk of obesity, particularly in 123 
children (21). Nonetheless, other studies using the ddPCR technique, (including one 124 
on >4,000 participants (22)), from diverse cohorts have shown no association 125 
between AMY1 CN and BMI (22, 23). Most recently, Shwan and colleagues reported 126 
on data from the 1958 Birth Cohort (1,400 subjects and >2,800 subjects from two 127 
disease cohorts from the Wellcome Trust Case Control Consortium), using paralogue 128 
ratio tests (PRTs) in genomic DNA and array comparative genomic hybridization 129 
data, and showed no evidence for association of AMY1 CN with BMI at any age 130 
point (24).  131 
 132 
Despite the controversy in this field based on the current literature outlined here, 133 
there does appear to be evidence, at least in some cohorts and particularly in 134 
children, for inverse association between AMY1 CN and BMI. However, the 135 
mechanism(s) that underlie this intriguing association remain incompletely 136 
understood. Furthermore, to our knowledge there are no published reports to date on 137 
possible associations between AMY1 CN and measures of metabolic status 138 
(including euglycemic hyperinsulinaemic clamps, stable isotopic measures of hepatic 139 
insulin sensitivity, abdominal magnetic resonance imaging [MRI] and H1 liver 140 





To address this important unanswered question, we explored associations of AMY1 142 
CN with metabolic status, body composition, macronutrient preference and fecal 143 
flora, in the most highly phenotyped cohort reported on to date. We also explored 144 
associations of AMY1 CN with blood glucose excursions following ingestion of 145 
glucose and oral starch challenge (OSC).  146 
 147 
Methods 148 
DNA Extraction: Samples and Techniques  149 
Urine and serum samples from ProFiMet cohort: For measurement of AMY1 CN, 150 
samples of Caucasian individuals (n=80) of the Protein, Fiber and Metabolic 151 
Syndrome (‘ProFiMet’) data set (clinicaltrials.gov, NCT00579657) were available 152 
(urine samples, n=74; serum samples, n=6). Participants of the ProFiMet study were 153 
overweight or obese, but non-diabetic. All participants had undergone extensive 154 
metabolic phenotyping including standard markers, assessment of dietary intake (5-155 
day food protocols including a weekend day), measurement of whole-body and 156 
hepatic Insulin Resistance (IR), assessment of body fat distribution through MRI 157 
scans and H1-spectroscopy (25), and assessment of a complete bile acid profile 158 
(26). In addition, each participant had assessment of various other biomarkers in 159 
blood, urine and feces, including dominant groups of the gut microbiota (27) and 160 
amino acid metabolic signatures (28). Details of the study design and participants 161 
are described in our core publication (25). The Ethics Committee of the University of 162 
Potsdam approved this study (BMBF-FKZ-0313826). All participants provided written 163 
informed consent. The Zymo Research Quick-DNA Urine Kit and protocol 164 
(Cambridge Bioscience, Cambridge, CB23 8SQ UK) was used for extraction of DNA 165 





(cellular and cell-free) DNA extraction. The QIAGEN QIAamp Blood Mini Kit and 167 
protocol (Qiagen UK) was used for extraction of DNA from serum (0.05ml kit elution 168 
buffer). Each serum sample (0.5ml) underwent DNA extraction. The yield of DNA 169 
was determined using a Qubit 3.0 fluorimeter (Life Technologies Ltd). 170 
 171 
Buccal samples from OSC cohort: Buccal swabs (Copan Flock Technologies 172 
4N6FLOQSwabs) were obtained from ThermoFisher Scientific, UK, Cat. #4479433. 173 
Following collection of buccal samples, the swabs were inserted into 2ml tubes with 174 
0.3ml of sterile DNAse-free water and agitated. Approximately 0.25ml of fluid was 175 
collected and DNA extracted using the Roche High Pure Viral Nucleic Acid Kit, 176 
obtained from Roche Diagnostics Ltd, UK (Product No. 11858874001). 177 
 178 
Whole blood EDTA and muscle samples for validation: Whole blood EDTA samples 179 
(n=43) from patients (both in-patients and out-patients) at University Hospitals 180 
Coventry and Warwickshire (UHCW) in the UK were used for DNA extraction. In 181 
addition, skeletal muscle biopsy samples from calf muscle from lower limb 182 
amputations (n=2) were obtained from the Arden Tissue Bank at UHCW, for the 183 
purpose of DNA extraction. A blood sample from a Chimpanzee (Pan troglodytes) 184 
was also provided by Chester Zoo, Cheshire, UK. The QIAGEN QIAamp Blood Mini 185 
Kit and protocol (Qiage UK) was used for extraction of DNA from whole blood. Each 186 
whole blood sample had a volume of 5ml.  187 
 188 
Cultured cell samples for validation: Validation of AMY1 CN assay was also provided 189 
by DNA that had already been extracted from existing cultured cell samples (n=7). 190 





were cell lines NA06993, NA07347, NA10835, NA11930, NA11993, NA12813 and 192 
NA18972. 193 
 194 
Analysis and Validation of AMY1 CN on Extracted DNA 195 
For all urine (n=74) and serum (n=6) samples from the ProFiMet cohort, and for the 196 
buccal samples collected from the OSC cohort, AMY1 CN was analysed using the 197 
‘droplet digital PCR’ (‘ddPCR’) technique, a recent practical technology for detection 198 
and quantitation of specific nucleic acid sequences (29). Digital PCR relies on 199 
dilution of target DNA and subsequent distribution into multiple, discrete replicate 200 
PCR reactions. Application of Poisson statistics enables calculation of the absolute 201 
measurement of target sequence concentration. We used ddPCR to determine 202 
AMY1 CN because this method allows highly repeatable quantitation of CN, and is 203 
less susceptible to PCR inhibition than qPCR. Furthermore ddPCR could be reliably 204 
applied to the low yield DNA samples available from the ProFiMet cohort. 205 
 206 
To validate the ddPCR technique, extracted DNA from each whole blood EDTA 207 
sample (n=43) or calf muscle (n=2) was analysed for assessment of AMY1 CN using 208 
the same ddPCR technique. For further validation, two separate techniques (PRT 209 
and ‘microsatellite typing’) were used to analyse AMY1 CN in the whole blood EDTA 210 
samples. For the PRT (PRTref12), we used the ‘Chromosome 12 Reference 211 
Paralogue’ to ascertain AMY1 CN in each sample, as described by Carpenter and 212 
colleagues (5). Regarding the ‘microsatellite typing’, Carpenter and colleagues 213 
described a TATC microsatellite region within the AMY1 gene region (5). Utilization 214 
of a PCR amplification of this microsatellite, followed by electrophoresis derived 215 





enabled estimation of AMY1 CN in informative individuals. PCR details were as 217 
described for the PRTref12, using TATC assay primers. A flowchart of DNA 218 
extractions and analyses, including validation of the ddPCR technique is shown in 219 
figure 1. To ascertain the precision of the ddPCR assay, two cultured cell samples 220 
from the Coriell Institute (Camden, NJ, USA) were assayed on several different days, 221 
and the mean AMY1 CNs and coefficients of variation calculated. 222 
 223 
The yield of DNA from urine and serum samples was much lower than that from 224 
blood samples. We therefore assessed the accuracy of ddPCR quantification of 225 
AMY1 CN at low DNA concentrations. DNA extracts from one Coriell sample 226 
(NA18972) and ten blood samples were diluted with water to DNA concentrations of 227 
0.05-0.28 ng/ul. These diluted extracts were subjected to ddPCR (7.5ul per reaction), 228 
and the AMY1 CN compared with those obtained by analysis of undiluted extracts. 229 
 230 
ProFiMet Cohort 231 
ProFiMet remains one of the most well-phenotyped and detailed cohorts of subjects 232 
with metabolic syndrome. Details of the ProFiMet cohort have been published (25-233 
28). The ProFiMet cohort consists of overweight and obese participants, with a wide 234 
range of BMI from 25Kgm-2 to 43Kgm-2. For the purpose of this study, data on body 235 
composition, liver fat content, measures of insulin sensitivity and hepatic glucose 236 
production, gut microbiota and macronutrient preferences were analysed. 237 
 238 
Body composition and liver fat content: Trained staff performed anthropometric 239 
measurements using standard methods. Body fat content was assessed using 1.5T 240 





lipid content was measured using proton magnetic resonance spectroscopy (1H-242 
MRS) (25, 30).  243 
 244 
Whole-body insulin resistance (IR) and insulin-induced suppression of hepatic 245 
glucose production: Euglycemic–hyperinsulinemic clamps (40 mU/kg/min) were 246 
performed in the overnight fasted state at weeks 0, 6, and 18 (n = 15–20 participants 247 
per group and study day), to assess whole-body IR (expressed as M-value). Tracer 248 
experiments were performed in a matched subset of participants (n = 9–11 249 
participants per group and study day), to measure (hepatic) endogenous glucose 250 
production (EGP), and EGP-suppression by insulin infusion. Calculation of hepatic 251 
IR (HEP-IR) was as follows: (EGP x fasting plasma insulin [FPI]) (30). Blood samples 252 
were drawn at timed intervals at baseline and throughout the clamp experiments, 253 
following 12-h overnight fasting. Samples were immediately chilled and centrifuged, 254 
and the supernatant fluid was aliquoted and stored at −80 °C until analysed. 255 
 256 
Dominant groups of the gut microbiota: Fecal collection and analysis of gut 257 
microbiota from fecal samples are detailed elsewhere (27). Briefly, fecal samples 258 
underwent Fluorescence in situ Hybridization (FisH) and bacterial enumeration by 259 
flow cytometry (27, 31). Flow cytometry data acquisition was performed with a FACS 260 
Calibur flow cytometer (Becton Dickinson) as described previously (32), using the 261 
settings of Mueller (27, 31). Changes in gut microbiota were measured for the 262 
following major bacterial population groups (respective oligonucleotide probe in 263 
brackets): Clostridium coccoides - Eubacterium rectale cluster (Erec482), Roseburia 264 
genus (Rrec584), Bacteroides-Prevotella (Bac303), Clostridium leptum cluster 265 





clostridial cluster IX (Prop853). Lactobacillus-Streptococcus group (Lab158) and 267 
Enterobacteria (Enter1432) were under the detection limit. (Roseburia, E. rectale and 268 
Faecalibacterium groups are major butyrate producers) (27). 269 
 270 
OSC Cohort  271 
For the OSC cohort, healthy participants (n=17) with no known history of Diabetes 272 
Mellitus or obesity were recruited from the community, for the sole purpose of this 273 
study. All participants within the OSC cohort were white and of British/Irish ethnicity. 274 
Each participant underwent a buccal swab as described, for determination of AMY1 275 
CN. The OSC cohort were divided into two subgroups, according to AMY1 CN. The 276 
high AMY1 CN subgroup (n=10) had a range of AMY1 CNs between 9 and 12 (mean 277 
CN 10). The low AMY1 CN subgroup (n=7) had a range of AMY1 CNs between 4 278 
and 6 (mean CN 5). Each participant was invited to attend for a fasting blood test 279 
(following a 12-hour fast) at 9am, followed by a standard OSC. The OSC consisted 280 
of 88g (dry weight) of basmati white rice (26.8g carbohydrate per 100g rice), cooked 281 
in tap water. Blood glucose measurements were based on finger-prick testing, using 282 
a Roche Accu-Chek Performa Nano Blood Glucose System. In addition to fasting 283 
tests, blood glucose measurements were also taken post-OSC at 30-min, 60-min, 284 











Statistical analyses 292 
Statistical analyses were conducted in SPSS (version 26 for Windows; SPSS Inc., 293 
Chicago, IL). For the ProFiMet cohort data, initial analyses involved derivation of 294 
Pearson correlation coefficients between AMY1 CN and the following indices of 295 
metabolic status: total visceral fat volume, measures of body composition, hepatic 296 
lipid content, whole-body insulin resistance, hepatic EGP, OGTT-derived OGIS 297 
score, macronutrient food preferences and fecal flora profiles. Detailed power 298 
calculations regarding the ProFiMet cohort have been documented previously (25). 299 
To explore independent associations of AMY1 CN with key markers of metabolic 300 
status, we performed linear regression multivariate analysis with serum adiponectin 301 
as a dependent variable. Independent variables included other, carefully selected 302 
outcome measures from the ProFiMet cohort to provide a detailed assessment of 303 
metabolic status, with addition of AMY1 CN. To avoid wide, multiple testing, we 304 
chose a minimalistic range of independent variables, to capture known key aspects 305 
of metabolic status. This represented only a small selection of the several hundred 306 
metabolic markers within the ProFiMet cohort. Therefore, we did not perform any 307 
corrections for multiple testing. For the OSC cohort data, we used independent 308 
sample t-tests for comparison between the low and high CN subgroups, including 309 
delta change in blood glucose readings from fasting to 30-min post-OSC time-points. 310 











DNA Extraction Success 318 
We define successful DNA extraction by sufficient DNA yield to perform a ddPCR 319 
assay for AMY1 CN. For the ProFiMet cohort, of the 98 urine samples available, 320 
DNA extraction was successful in 74 samples. For the remaining subjects (n=24) 321 
where DNA extraction from urine was unsuccessful, DNA extraction was attempted 322 
from serum samples from the same subjects. Of these, DNA was extracted 323 
successfully from serum samples (n=6), providing a total of n=80 DNA samples from 324 
the ProFiMet cohort, from which the DNA recovered was within the range 0.02-325 
16.7ng/μl; median 0.15ng/μl. Given that all of the urine and serum samples from the 326 
ProFiMet cohort had already undergone centrifugation, there was limited cellular 327 
material available for DNA extraction in each sample. For this reason, it was not 328 
possible to obtain any DNA from some of the urine (n=24) and serum (n=18) 329 
samples from the ProFiMet cohort. DNA extraction was successful in all of the whole 330 
blood EDTA (n=43) and calf muscle (n=2) samples, and for all of the buccal (n=17) 331 
samples in the OSC cohort. 332 
 333 
Validation and Precision of ddPCR Technique for AMY1 CN Analysis 334 
For all of the reference DNA materials (seven cell lines), the AMY1 CN assessed by 335 
all three methods (PRT, microsatellite and ddPCR) was equivalent to values reported 336 
previously (5). We subsequently applied these three methods for AMY1 CN 337 
assessment to anonymised DNA, extracted from 45 samples (EDTA whole blood 338 
[n=43] and skeletal muscle [n=2] samples), obtained from the Arden Tissue Bank at 339 
UHCW. Statistically, there was no significant difference between AMY1 CN 340 





Microsatellite profiling was uninformative for six individuals due to insufficient allele 342 
length variation. In a further eight individuals, the microsatellite profile calculated 343 
using the most parsimonious ratio indicated a CN that was half the number 344 
estimated by ddPCR and PRT. Application of an alternate CN profile in these cases 345 
resulted in AMY1 CN evaluation consistent with data derived from the other 346 
techniques.   347 
 348 
In view of the fact that the paralogue and microsatellite assays were human-specific, 349 
we could only apply the AMY1 ddPCR assay to the DNA extracted from an EDTA 350 
whole blood sample, taken from a chimpanzee (Chester Zoo, UK). This revealed a 351 
CN of 2 (ie. one copy per chromosome), as expected (7). Assessment of the 352 
accuracy of ddPCR to determine AMY1 CN in low yield DNA samples resulted in 353 
good correlations at low CN, but with less accuracy at high copy number (Mann 354 
Whitney U test p-value=0.91). Regarding ddPCR precision, separate analyses on 355 
different days for Coriell sample NA 11930 (n=7; nominal CN 2) showed a mean CN 356 
of 1.9 (CV 1.9%), and for Coriell sample NA 07347 (n=6; nominal CN 10) showed a 357 
mean CN of 10.4 (CV 5.8%). Therefore, we believe that the ddPCR assay used in 358 
our study is a robust and reliable method for assessment of human AMY1 CN, even 359 
for samples with a low yield of DNA. 360 
 361 
Distribution of AMY1 CN for the ProfiMet and OSC Cohorts 362 
A histogram showing the distribution of AMY1 CN across the ProFiMet cohort is 363 
shown in figure 2. The CN for the AMY1 gene in the ProFiMet individuals ranged 364 
from 2 to 10, compared with a range of 4 to 12 in the OSC cohort. The majority of the 365 





remainder (n=11, 13.75%) had extreme CNs of the AMY1 gene, either 2 copies or >8 367 
copies. Descriptive statistics for the AMY1 CN between the ProFiMet and OSC 368 
cohorts revealed mean 4.7 (SD 1.9) and 7.9 (SD 2.9) respectively. 369 
 370 
Pearson Correlation Coefficients for the ProfiMet Cohort (table 1) 371 
There was a highly significant inverse correlation of AMY1 CN with total visceral fat 372 
volume (correlation coefficient -0.33, P=0.004), and visceral fat volume within the 373 
umbilical area (correlation coefficient -0.324, P=0.004). Although there was an 374 
inverse correlation of AMY1 CN with BMI (correlation coefficient -0.214), this failed to 375 
reach significance (P=0.057). There was an inverse correlation between AMY1 CN 376 
and lean mass (correlation coefficient -0.216), which just failed to reach significance 377 
(P=0.055). There were no significant associations between AMY1 CN and total fat 378 
volume, fat mass, intrahepatic lipid content, umbilical subcutaneous adipose tissue 379 
volume, whole-body insulin resistance, HOMA-IR, insulin sensitivity index or hepatic 380 
EGP. However, there was a significant direct correlation between AMY1 CN and 381 
(OGTT-derived) OGIS score (correlation coefficient 0.259, P=0.02). Regarding lipid 382 
profile, there was a significant correlation between AMY1 CN and serum HDL-383 
cholesterol (correlation coefficient 0.325, P=0.003), but no significant associations 384 
with any of the other components of lipid profile, including triglycerides. There was a 385 
significant direct correlation between AMY1 CN and serum adiponectin (correlation 386 
coefficient 0.249, P=0.026). There were no significant correlations with serum leptin, 387 
acylated ghrelin, Fibroblast Growth Factor-21 (FGF-21), interleukin 10 or C-reactive 388 
protein (CRP). AMY1 CN showed no significant correlation with any measure of fecal 389 
microbiota (FisH analysis). There was no correlation of AMY1 CN with dietary 390 





magnesium, protein, meat, fish, milk, legumes, eggs, poultry, carbohydrates, 392 
cholesterol, polyunsaturated fatty acids (PUFA), monounsaturated fatty acids 393 
(MUFA) and short chain fatty acids (SFA). Associations between AMY1 CN and total 394 
visceral fat volume, umbilical visceral fat volume, OGIS score, serum fasting HDL-395 
Cholesterol and serum adiponectin are shown graphically in figure 3. 396 
 397 
Linear Regression Multivariate Analyses for the ProFiMet Cohort 398 
Given the central role played by adiponectin as a regulator of metabolic status, and 399 
the excellent utility of adiponectin as an indicator of metabolic status, we chose 400 
serum adiponectin as a dependent variable for linear regression multivariate 401 
analysis. In addition to AMY1 CN, we used a carefully selected panel of metabolic 402 
markers from the ProFiMet cohort as independent variables, to provide a detailed 403 
assessment of metabolic status. These included age, BMI, total fat volume, 404 
intrahepatic lipid content, whole body insulin resistance, hepatic EGP, fasting 405 
glucose, fasting insulin, HbA1C, serum triglycerides, CRP, Plasminogen Activator 406 
Inhibitor-1 (PAI-1) and FGF-21. Linear regression multivariate analysis revealed a 407 
significant independent association of serum adiponectin with AMY1 CN (Beta=0.29; 408 
P=0.03), and with age (Beta=0.60; P<0.0001). There were no other significant 409 
independent associations between serum adiponectin and any other independent 410 
variable. Following a repeat linear regression multivariate analysis with serum 411 
adiponectin as a dependent variable, and with the addition of gender as an 412 
independent variable, revealed significant independent associations of serum 413 
adiponectin with AMY1 CN (Beta=0.26; P=0.046), age (Beta=0.59; P<0.001) and 414 
gender (Beta=0.35; P=0.01). Interestingly, one-way ANOVA showed no relationship 415 





Independent t-test Comparisons for the Oral Starch Challenge Cohort 417 
For the OSC cohort, the high AMY1 CN subgroup had a lower mean fasting blood 418 
glucose concentration than the low AMY1 CN subgroup (4.9mmol/l [SEM 0.14] vs 419 
5.8mmol/l [SEM 2.9] respectively, p=0.011). Delta change (mean) in blood glucose 420 
concentration from fasting to 30-min post-OSC was significantly greater in the high 421 
AMY1 CN subgroup compared with the low AMY1CN subgroup (mean 1.7mmol/l 422 
[SEM 0.6] vs 0.9mmol/l [SEM 0.9] respectively, p = 0.016). 423 
 424 
Discussion 425 
In this most highly phenotyped ProFiMet cohort, our study is the most 426 
comprehensively reported on to date regarding association of human AMY1 CN with 427 
metabolic and dietary parameters. We demonstrate that high AMY1 CN associates 428 
significantly with a favourable metabolic profile, including lower visceral fat volume, 429 
higher serum levels of adiponectin and HDL-cholesterol, and enhanced glucose 430 
absorption following an oral glucose load. We also demonstrate important negative 431 
outcomes, including absence of any association between AMY1 CN and whole-body 432 
insulin resistance, hepatic EGP, macronutrient preference or pattern of fecal flora. 433 
Our data reveal pronounced plasma glucose excursions following a glucose load in 434 
those with a high AMY1 CN, without differences in hepatic EGP or measures of 435 
insulin sensitivity. Furthermore, high AMY1 CN associated with a more pronounced 436 
blood glucose excursion following OSC in a separate healthy cohort. These data are 437 
consistent with co-evolution of high AMY1 CN (with attendant enhanced salivary 438 
digestion of starch to maltose, and thereafter absorbable glucose monomers), with 439 
optimized efficiency of glucose absorption across the upper GI tract. Further studies 440 





efficiency, and potential role for AMY1 CN and other (potentially haplotypic) genetic 442 
variants in this process.  443 
 444 
The ddPCR is a relatively new technique in which the PCR is executed in a multitude 445 
of tiny droplets held in oil suspension, as opposed to conventional PCR which is 446 
performed in a single solution. One advantage of ddPCR is that only small amounts 447 
of DNA are required. This is evidenced by the fact that in our study, sufficient DNA 448 
was extracted from urine and serum samples, in which there were very low yields of 449 
DNA. To validate our data, a rigorous procedure involving two totally different 450 
methods, microsatellite typing and the PRT were adopted. Agreement was generally 451 
excellent amongst data derived from these three separate types of test, with only 452 
eight samples giving half the expected values in the strictest interpretation of the 453 
microsatellite data. The excellent agreement amongst the data derived from the 454 
three methods employed, justifies our decision to use ddPCR in the determination of 455 
AMY1 CN in the ProFiMet samples. 456 
 457 
Although BMI is limited as a reliable indicator of underlying metabolic status, most 458 
studies reported to date have focused solely on association between AMY1 CN and 459 
BMI. As discussed earlier, one of the most definitive and highly powered genetic 460 
studies in the field, reported on AMY1 CN in >6,000 subjects and demonstrated a 461 
reciprocal association of AMY1 CN with BMI, and direct correlations between AMY1 462 
CN, amylase gene expression and serum levels of amylase (16). Our study is unique 463 
amongst the reported literature on AMY1 CNV, in providing a much more detailed 464 
and comprehensive assessment of metabolic status than BMI can provide. This 465 





resistance and hepatic EGP in the context of AMY1 CN. Although a trend for 467 
reciprocal association between AMY1 CN and BMI was shown, this just failed to 468 
reach statistical significance. A likely explanation is that the ProFiMet cohort only 469 
included overweight or obese, without normal weight participants. 470 
 471 
There remains controversy within the literature regarding association between AMY1 472 
CN and BMI. Variation in dietary preferences (including dietary starch ingestion) 473 
between populations studied may explain some of the differences in strength of 474 
association between AMY1 CN and BMI. In a large Swedish cohort, AMY1 CN had a 475 
significant direct association with BMI in those subjects with high starch intake (1, 476 
33), likely mediated through enhanced digestion of starch, and absorption of glucose 477 
from a starchy diet in those with a higher AMY1 CN, thereby increasing susceptibility 478 
to weight gain (1, 33). In contrast, our data refute any important role for dietary 479 
starch, or other macronutrient preference in the mediation of association between 480 
AMY1 CN and metabolic status, including BMI. Our data also refute the notion that 481 
AMY1 CN mediates metabolic influence through changes in colonic undigested 482 
starch, as we showed no association of AMY1 CN with changes in gut microbiota, 483 
colonic fermentation rates or levels of colonic SFAs (1, 21, 34). 484 
 485 
In one study, AMY1 CN correlated directly with a more pronounced excursion of 486 
insulin within the early postprandial phase (‘pre-absorptive’ or ‘Cephalic Phase 487 
Insulin Response’ [CPIR]) following starch ingestion, and lower postprandial glucose 488 
responses (9). Oral sensory stimulation triggers CPIR, the ‘anticipatory’ phase of 489 
digestion, mediated by autonomic mechanisms (35). CPIR primes the body for 490 





postprandial glucose tolerance and prevention of dysglycemia (9, 12). A higher 492 
AMY1 CN may associate with greater metabolic efficiency, particularly with regard to 493 
oral starch handling. In a further study, enhanced CPIR associated with salivary 494 
amylase levels (9). In people with high levels of salivary amylase, activation of 495 
lingual taste receptors may occur through orally released carbohydrate, thereby 496 
triggering CPIR through an autonomic process (1, 9).  497 
 498 
We demonstrated an enhanced response of insulin following OGTT in those with 499 
high AMY1 CN in the ProFiMet cohort. However, this rise in the level of serum insulin 500 
following oral glucose ingestion occurred in response to enhanced early glucose 501 
absorption in those with a high AMY1 CN. This insulin response to oral glucose 502 
ingestion therefore appears to be separate from any independent effect of AMY1 CN 503 
on pancreatic insulin response, hepatic EGP or insulin sensitivity, and therefore 504 
seems unlikely to be mediated directly through CPIR. It is important to highlight that 505 
there was only a transient difference in early post-prandial plasma glucose levels 506 
following OGTT according to AMY1 CN in the ProFiMet cohort. Although this 507 
transient early postprandial rise in plasma glucose in those participants with a higher 508 
AMY1 CN may confer metabolic risk, we hypothesize that a more likely scenario is 509 
that the associated pronounced early postprandial rise in serum insulin in those with 510 
a higher AMY1 CN in the context of equivalent hepatic glucose output and insulin 511 
sensitivity (according to AMY1 CN), would be expected to drive postprandial cellular 512 
uptake of glucose and confer other metabolic benefits. Our data are therefore 513 
consistent with association of higher AMY1 CN with a favourable metabolic profile. 514 





implications of AMY1 CN, particularly regarding postprandial glucose handling and 516 
cellular effects of insulin response.  517 
 518 
Consistent with the data from the ProFiMet cohort, our data from the participants 519 
who underwent OSC also showed a more pronounced glucose excursion for the 520 
subgroup with a higher AMY1 CN. In contrast however, data from a study reported 521 
by Tan and colleagues on healthy men (n=75) from a multi-ethnic Asian population, 522 
showed no significant association between AMY1 CN and glycemic response to rice 523 
ingestion (36). Interestingly, mastication parameters (number of chews and chewing 524 
time per mouthful) did associate with glycaemic response to ingested rice (36). A 525 
further study was reported by Heianza and colleagues on genetic variants in AMY1 526 
and AMY2 CN in >690 overweight and obese participants, randomly assigned to 527 
diets varying in macronutrient content (37). In this study, although changes in body 528 
weight and waist circumference were significantly different according to AMY1-AMY2 529 
rs11185098 genotype, at 24-months follow-up there was no significant association 530 
between fasting plasma glucose level and AMY1-AMY2 genotype (37). Further 531 
studies are required to explore the association between AMY1 CN and glucose 532 
homeostasis, including fasting glucose and glycemic response to starch ingestion. 533 
Future research should focus on the mechanisms whereby AMY1 CN influences 534 
starch digestion, glucose absorption and early insulin release, and how these 535 
complex mechanisms contribute to blood glucose excursions following ingestion of 536 
carbohydrates, including starch.   537 
 538 
Similar to data from other reported studies, we demonstrated a significant positive 539 





adiponectin (39). Although speculative, serum amylase may confer cardio-protective, 541 
anti-inflammatory and insulin-sensitising properties (40). However, our assessment 542 
did not enable any exploration of underlying mechanisms, and it is not possible to 543 
infer any causal association between AMY1 CN and HDL-cholesterol and 544 
adiponectin. However, adiponectin and HDL-cholesterol are both known to confer 545 
cardio-metabolic benefits (1). Furthermore, we demonstrated an independent and 546 
direct association between AMY1 CN and serum levels of adiponectin. We therefore 547 
provide evidence for promotion of an association between high AMY1 CN and a 548 
favourable cardio-metabolic profile.  549 
 550 
Our study does have some limitations including its cross-sectional design, thereby 551 
precluding any exploration of association between AMY1 CN and temporal migration 552 
of metabolic indices. Furthermore, a lack of data on either salivary or serum amylase 553 
concentrations limited potential insights implicating these factors in the mediation of 554 
association between AMY1 CN and metabolic status. Our ProFiMet cohort only had 555 
AMY1 CN ranging between 2 and 10 copies, rather than the full range of copies 556 
(n=2-27) that has been reported in human populations (1). A likely explanation is that 557 
the ProFiMet cohort is relatively homogeneous, with Caucasian participants from the 558 
German Berlin-Potsdam region, with BMI restricted to the overweight and obese 559 
ranges. Furthermore, the OSC cohort had a relatively restricted range of AMY1 CN 560 
ranging between 4 and 12. A likely explanation is the ethnic homogeneity of the OSC 561 
cohort, with all OSC participants being white and of British/Irish origin. Finally, we 562 
used FisH analyses rather than shotgun metagenomics for gut microbiota 563 
assessment. Therefore, our conclusions regarding lack of differences in gut 564 





are required across wider cohorts, to explore associations between AMY1 CN and 566 
fecal floral signature, using gold standard methodologies. 567 
 568 
To summarize, we demonstrate significant direct associations between AMY1 CN 569 
and serum adiponectin, HDL-cholesterol and efficiency of glucose absorption 570 
following both oral glucose load and OSC. We also show reciprocal association 571 
between AMY1 CN and visceral fat volume. We exclude any mediating effects of 572 
macronutrient food preference, insulin resistance or fecal floral signature on the 573 
associations between AMY1 CN and metabolic status. In those subjects with a 574 
higher AMY1 CN, a more pronounced glucose excursion following an oral glucose 575 
load, without concomitant changes in whole-body or hepatic IR, strongly suggests 576 
improved efficiency of glucose absorption across the upper GI tract. We hypothesize 577 
co-evolution of enhanced salivary starch digestion (through increased AMY1 CN), 578 
with genetic determinants of enhanced upper GI glucose absorption, and early 579 
postprandial insulin release. As such, postprandial metabolic efficiency through 580 
optimized glucose absorption across the upper GI tract, and efficient assimilation of 581 
absorbed glucose through early insulin release, would complement early enhanced 582 
salivary starch breakdown (in those with higher AMY1 CN). In short, we hypothesize 583 
that key physiological aspects of starch digestion, glucose absorption and 584 
assimilation, are connected through genetic and/or other mechanisms. This model 585 
should be used as a focus for future research, to gain further insight into the 586 
mechanisms that mediate association between human AMY1 CN and metabolic 587 








We are grateful to our Micropathology colleagues, Dr Jack Hassall and Marie Voice 592 
for statistical advice and Jennifer Holden and Ellie Phillips for laboratory assistance. 593 
 594 
Statement of Authors’ Contributions 595 
This research study protocol was designed by TMB, DB, DBR and MOW. Execution 596 
of the study was led by AAB, PJDE and DB, with substantial input from SPB and RC. 597 
Data analysis was conducted by TMB, DB and MOW. All authors contributed to the 598 
preparation of this manuscript, and write-up was mainly coordinated by TMB with 599 
input from DB, DJC, AFP, DBR and MOW.  All authors have read and approved this 600 






1. Elder PJD, Ramsden DB, Burnett D, Weickert MO, Barber TM. Human 
amylase gene copy number variation as a determinant of metabolic state. Expert 
Rev Endocrinol Metab. 2018;13(4):193-205. 
2. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic 
studies of body mass index yield new insights for obesity biology. Nature. 
2015;518(7538):197-206. 
3. Waalen J. The genetics of human obesity. Transl Res. 2014;164(4):293-301. 
4. Dracopoli NC, Meisler MH. Mapping the human amylase gene cluster on the 
proximal short arm of chromosome 1 using a highly informative (CA)n repeat. 
Genomics. 1990;7(1):97-102. 
5. Carpenter D, Dhar S, Mitchell LM, Fu B, Tyson J, Shwan NA, et al. Obesity, 
starch digestion and amylase: association between copy number variants at human 
salivary (AMY1) and pancreatic (AMY2) amylase genes. Hum Mol Genet. 
2015;24(12):3472-80. 
6. Groot PC, Mager WH, Frants RR. Interpretation of polymorphic DNA patterns 
in the human alpha-amylase multigene family. Genomics. 1991;10(3):779-85. 
7. Inchley CE, Larbey CD, Shwan NA, Pagani L, Saag L, Antao T, et al. Selective 
sweep on human amylase genes postdates the split with Neanderthals. Sci Rep. 
2016;6:37198. 
8. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, et al. 
Detection of large-scale variation in the human genome. Nat Genet. 2004;36(9):949-
51. 
9. Mandel AL, Breslin PA. High endogenous salivary amylase activity is 
associated with improved glycemic homeostasis following starch ingestion in adults. 
J Nutr. 2012;142(5):853-8. 
10. Mandel AL, Peyrot des Gachons C, Plank KL, Alarcon S, Breslin PA. 
Individual differences in AMY1 gene copy number, salivary alpha-amylase levels, 
and the perception of oral starch. PLoS One. 2010;5(10):e13352. 
11. Santos JL, Saus E, Smalley SV, Cataldo LR, Alberti G, Parada J, et al. Copy 
number polymorphism of the salivary amylase gene: implications in human nutrition 





12. Peyrot des Gachons C, Breslin PA. Salivary Amylase: Digestion and Metabolic 
Syndrome. Curr Diab Rep. 2016;16(10):102. 
13. Fernandez CI, Wiley AS. Rethinking the starch digestion hypothesis for AMY1 
copy number variation in humans. Am J Phys Anthropol. 2017;163(4):645-57. 
14. Perry GH, Dominy NJ, Claw KG, Lee AS, Fiegler H, Redon R, et al. Diet and 
the evolution of human amylase gene copy number variation. Nat Genet. 
2007;39(10):1256-60. 
15. Yang ZM, Lin J, Chen LH, Zhang M, Chen WW, Yang XR. The roles of AMY1 
copies and protein expression in human salivary alpha-amylase activity. Physiol 
Behav. 2015;138:173-8. 
16. Falchi M, El-Sayed Moustafa JS, Takousis P, Pesce F, Bonnefond A, 
Andersson-Assarsson JC, et al. Low copy number of the salivary amylase gene 
predisposes to obesity. Nat Genet. 2014;46(5):492-7. 
17. Choi YJ, Nam YS, Yun JM, Park JH, Cho BL, Son HY, et al. Association 
between salivary amylase (AMY1) gene copy numbers and insulin resistance in 
asymptomatic Korean men. Diabet Med. 2015;32(12):1588-95. 
18. Mejia-Benitez MA, Bonnefond A, Yengo L, Huyvaert M, Dechaume A, Peralta-
Romero J, et al. Beneficial effect of a high number of copies of salivary amylase 
AMY1 gene on obesity risk in Mexican children. Diabetologia. 2015;58(2):290-4. 
19. Ooi DS, Tan VM, Ong SG, Chan YH, Heng CK, Lee YS. Differences in AMY1 
Gene Copy Numbers Derived from Blood, Buccal Cells and Saliva Using 
Quantitative and Droplet Digital PCR Methods: Flagging the Pitfall. PLoS One. 
2017;12(1):e0170767. 
20. Viljakainen H, Andersson-Assarsson JC, Armenio M, Pekkinen M, Pettersson 
M, Valta H, et al. Low Copy Number of the AMY1 Locus Is Associated with Early-
Onset Female Obesity in Finland. PLoS One. 2015;10(7):e0131883. 
21. Bonnefond A, Yengo L, Dechaume A, Canouil M, Castelain M, Roger E, et al. 
Relationship between salivary/pancreatic amylase and body mass index: a systems 
biology approach. BMC Med. 2017;15(1):37. 
22. Usher CL, Handsaker RE, Esko T, Tuke MA, Weedon MN, Hastie AR, et al. 
Structural forms of the human amylase locus and their relationships to SNPs, 





23. Yong RY, Mustaffa SB, Wasan PS, Sheng L, Marshall CR, Scherer SW, et al. 
Complex Copy Number Variation of AMY1 does not Associate with Obesity in two 
East Asian Cohorts. Hum Mutat. 2016;37(7):669-78. 
24. Shwan NAA, Armour JAL. No Evidence for Association of BMI with Salivary 
Amylase Gene Copy Number in the UK 1958 Birth Cohort. Obesity (Silver Spring). 
2019;27(9):1533-8. 
25. Weickert MO, Roden M, Isken F, Hoffmann D, Nowotny P, Osterhoff M, et al. 
Effects of supplemented isoenergetic diets differing in cereal fiber and protein 
content on insulin sensitivity in overweight humans. Am J Clin Nutr. 2011;94(2):459-
71. 
26. Weickert MO, Hattersley JG, Kyrou I, Arafat AM, Rudovich N, Roden M, et al. 
Effects of supplemented isoenergetic diets varying in cereal fiber and protein content 
on the bile acid metabolic signature and relation to insulin resistance. Nutr Diabetes. 
2018;8(1):11. 
27. Weickert MO, Arafat AM, Blaut M, Alpert C, Becker N, Leupelt V, et al. 
Changes in dominant groups of the gut microbiota do not explain cereal-fiber 
induced improvement of whole-body insulin sensitivity. Nutr Metab (Lond). 2011;8:90. 
28. Hattersley JG, Pfeiffer AF, Roden M, Petzke KJ, Hoffmann D, Rudovich NN, et 
al. Modulation of amino acid metabolic signatures by supplemented isoenergetic 
diets differing in protein and cereal fiber content. J Clin Endocrinol Metab. 
2014;99(12):E2599-609. 
29. Huggett JF, Foy CA, Benes V, Emslie K, Garson JA, Haynes R, et al. The 
digital MIQE guidelines: Minimum Information for Publication of Quantitative Digital 
PCR Experiments. Clin Chem. 2013;59(6):892-902. 
30. Hattersley JG, Mohlig M, Roden M, Arafat AM, Loeffelholz CV, Nowotny P, et 
al. Quantifying the improvement of surrogate indices of hepatic insulin resistance 
using complex measurement techniques. PLoS One. 2012;7(6):e39029. 
31. Mueller S, Saunier K, Hanisch C, Norin E, Alm L, Midtvedt T, et al. Differences 
in fecal microbiota in different European study populations in relation to age, gender, 
and country: a cross-sectional study. Appl Environ Microbiol. 2006;72(2):1027-33. 
32. Rigottier-Gois L, Bourhis AG, Gramet G, Rochet V, Dore J. Fluorescent 
hybridisation combined with flow cytometry and hybridisation of total RNA to analyse 
the composition of microbial communities in human faeces using 16S rRNA probes. 





33. Rukh G, Ericson U, Andersson-Assarsson J, Orho-Melander M, Sonestedt E. 
Dietary starch intake modifies the relation between copy number variation in the 
salivary amylase gene and BMI. Am J Clin Nutr. 2017;106(1):256-62. 
34. Weickert MO. What dietary modification best improves insulin sensitivity and 
why? Clin Endocrinol (Oxf). 2012;77(4):508-12. 
35. Ahren B, Holst JJ. The cephalic insulin response to meal ingestion in humans 
is dependent on both cholinergic and noncholinergic mechanisms and is important 
for postprandial glycemia. Diabetes. 2001;50(5):1030-8. 
36. Tan VM, Ooi DS, Kapur J, Wu T, Chan YH, Henry CJ, et al. The role of 
digestive factors in determining glycemic response in a multiethnic Asian population. 
Eur J Nutr. 2016;55(4):1573-81. 
37. Heianza Y, Sun D, Wang T, Huang T, Bray GA, Sacks FM, et al. Starch 
Digestion-Related Amylase Genetic Variant Affects 2-Year Changes in Adiposity in 
Response to Weight-Loss Diets: The POUNDS Lost Trial. Diabetes. 
2017;66(9):2416-23. 
38. Teff KL, Engelman K. Oral sensory stimulation improves glucose tolerance in 
humans: effects on insulin, C-peptide, and glucagon. Am J Physiol. 1996;270(6 Pt 
2):R1371-9. 
39. Lee JG, Park SW, Cho BM, Lee S, Kim YJ, Jeong DW, et al. Serum amylase 
and risk of the metabolic syndrome in Korean adults. Clin Chim Acta. 2011;412(19-
20):1848-53. 
40. Nakajima K, Muneyuki T, Munakata H, Kakei M. Revisiting the 
















Table 1: Pearson Correlation Coefficients with AMY1 CN 
(Data from ProFiMet cohort, n=80; P<0.05 is statistically significant, marked with* and highlighted in 
bold type; NS=non-significant; SIB=stable isotope basal; SISS=stable isotope steady state) 
 
Variable Correlation Coefficient P-value 
 
Body composition 
BMI -0.214 0.057 
Fat Mass (BodPod) -0.085 NS 
Lean Mass (BodPod) -0.216 0.055 
Total Fat Volume -0.070 NS 
Subcutaneous adipose tissue (umbilical) 0.025 NS 
 
Visceral and hepatic indices 
Total Visceral Fat Volume -0.330 0.004* 
Visceral adipose tissue (umbilical) -0.324 0.004* 
Intrahepatic Lipid Content -0.094 NS 
Hepatic Endogenous Glucose Production 
(SIB) 
-0.047 NS 




Biochemical metabolic markers 
Fasting Glucose 0.003 NS 
Fasting Insulin -0.141 NS 
OGIS (OGTT-derived) 0.259 0.02* 
Whole-body insulin resistance 0.129 NS 
HOMA-IR -0.128 NS 
Insulin Sensitivity Index 0.114 NS 
HbA1C -0.126 NS 
Serum Total Cholesterol 0.091 NS 
Serum HDL Cholesterol 0.325 0.003* 
Serum triglycerides -0.110 NS 
Serum LDL Cholesterol 0.001 NS 
NEFA 0.001 NS 
 
Inflammatory markers and adipokines  
Serum CRP -0.137 NS 
Serum PAI-1 -0.04 NS 
Serum Interleukin 10 0.070 NS 
Serum FGF-21 -0.028 NS 




Serum ghrelin 0.227 0.044* 
Serum acylated ghrelin 0.158 NS 
Serum leptin 0.077 NS 
 
Macronutrient Intake 
Alcohol intake -0.200 NS 
Total energy intake -0.155 NS 
Total fibre intake 0.129 NS 
Soluble fibre intake 0.107 NS 
Insoluble fibre intake 0.174 NS 
Magnesium intake -0.130 NS 
Protein intake -0.200 NS 
Red meat intake -0.102 NS 
Fish intake 0.110 NS 
Milk intake -0.131 NS 
Legume intake 0.021 NS 
Egg intake -0.078 NS 
Poultry intake -0.116 NS 
Carbohydrate intake -0.135 NS 
Cholesterol intake -0.110 NS 
PUFA intake 0.041 NS 
MUFA intake -0.052 NS 








Figure 1: Flowchart of DNA extractions and analyses, including validation of the ddPCR 
technique 
OSC=oral starch challenge; mus=muscle; PRT=Paralogue Ratio Test; ddPCR=droplet digital 





Figure 2: Histogram showing the distribution of AMY1 CN amongst the ProFiMet Cohort 
 
 
Figure 3: Associations between AMY1 CN and total visceral fat volume, umbilical visceral fat 
volume, OGIS score, serum fasting HDL-Cholesterol and serum adiponectin amongst the 
ProFiMet Cohort (mean values and standard error of the mean [SEM]) 
AMY1: The human salivary amylase gene 
CN: Copy Number  
HDL: High Density Lipoprotein 
OGIS: Oral Glucose Insulin Sensitivity 
 
 
